Alex Sapir, Fulcrum Therapeutics CEO
July 10, 2023 10:45 AM EDTUpdated 11:12 AM
Deals

Ful­crum inks dis­cov­ery deal with Camp4 Ther­a­peu­tics

Paul Schloesser

Associate Editor

With a new CEO at the helm and its hema­to­log­i­cal pro­gram still un­der a clin­i­cal hold, Ful­crum Ther­a­peu­tics has signed a li­cens­ing and dis­cov­ery deal …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

A service from the Financial Times